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REVIEW
Engineered BDNF producing cells as a potential treatment for neurologic disease
Peter Denga,b, Johnathon D. Andersona, Abigail S. Yub, Geralyn Annetta, Kyle D. Finka and Jan A. Noltaa
aStem Cell Program and Institute for Regenerative Cures, University of California Davis Health Systems, Sacramento, CA, USA; bGenome Center,
MIND Institute, and Biochemistry and Molecular Medicine, University of California, Davis, CA, USA
ABSTRACT
Introduction: Brain-derived neurotrophic factor (BDNF) has been implicated in wide range of neurolo-
gical diseases and injury. This neurotrophic factor is vital for neuronal health, survival, and synaptic
connectivity. Many therapies focus on the restoration or enhancement of BDNF following injury or
disease progression.
Areas covered: The present review will focus on the mechanisms in which BDNF exerts its beneficial
functioning, current BDNF therapies, issues and potential solutions for delivery of neurotrophic factors
to the central nervous system, and other disease indications that may benefit from overexpression or
restoration of BDNF.
Expert opinion: Due to the role of BDNF in neuronal development, maturation, and health, BDNF is
implicated in numerous neurological diseases making it a prime therapeutic agent. Numerous studies
have shown the therapeutic potential of BDNF in a number of neurodegenerative disease models and
in acute CNS injury, however clinical translation has fallen short due to issues in delivering this
molecule. The use of MSC as a delivery platform for BDNF holds great promise for clinical advancement
of neurotrophic factor restoration. The ease with which MSC can be engineered opens the door to the
possibility of using this cell-based delivery system to advance a BDNF therapy to the clinic.
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1. Brain-derived neurotrophic factor introduction
There is an increasing body of evidence for the importance of
neurotrophins (NTF) and their role in developmental and mature
neuronal cell health. The first NTF, nerve growth factor (NGF), was
discovered in the 1950s by a group of embryologists,[1] and over
the past 50 years additional NTFs such as brain-derived neuro-
trophic factor (BDNF) in pig brain in 1982,[2] neurotrophin 3
(NT3),[3] and neurotrophin 4 (NT4) [4] have been discovered. In
the mature brain, NTFs have two primary functions. First, NTFs
offer trophic support that enhances neurogenesis and neuropro-
tection. Second, NTFs are potent modulators of synaptic plasti-
city, a defining role in learning throughout life. BDNF is of
potential interest due to the widespread prevalence of TrkB,
BDNF’s preferential receptor in the central nervous system
(CNS), and its role in potentiating neuronal cell fate through
various canonical signaling cascades [5] that influence survival,
neuronal outgrowth,[6,7] and plasticity.[8] Loss of BDNF has been
implicated in a number of neurodegenerative diseases,[9] while
restoration or addition of exogenous BDNF has shown a physio-
logic therapeutic effect [10–12] (Figure 1).
This review will briefly describe the gene expression and
signal transduction pathways of NTFs, the role of BDNF in the
developing and mature nervous system, and its indication in a
number of neurodegenerative diseases. The review will also
summarize the preclinical and clinical research on BDNF, chal-
lenges with in vivo delivery of BDNF, and application to new
disease indications.
1.1. BDNF mechanism
NTFs are a class of growth factors with vital roles in the
development of mature neuronal systems. Mature neurotro-
phin action is mediated by high-affinity tropomyosin receptor
kinase (Trk) family of receptors which are signaled by dimer-
ization of two receptor molecules. The Trk receptor family
consists of a TrkA, TrkB, and TrkC subtype, and activation is
characterized by intracellular autophosphorylation and ensu-
ing secondary signaling cascades following receptor dimeriza-
tion. NTFs demonstrate preferential binding to specific Trk
receptors. NGF preferentially binds to TrkA, BDNF and NT4 to
TrkB, and NT3 to TrkC.[13] Interestingly, p75NTR has equally
low affinity for mature NTFs but high-affinity toward pro-neu-
trophins. BDNF is initially synthesized as a precursor protein
known as preproBDNF that is cleaved to proBDNF that is
further cleaved into mature BDNF by tissue plasminogen acti-
vator. When bound to TrkB, mature BDNF induces receptor
dimerization, and autophosphorylates tyrosine residues that
initiates secondary cascades that regulate neurogenesis,
synaptic plasticity, and apoptosis.[14] This is achieved by
three major signaling pathways: the phosphatidyl inositol 3-
kinase (PI3K)–serine–threonine kinase (AKT), mitogen-acti-
vated protein kinase (MAPK) extracellular-related kinase (ERK)
pathway, and the phospholipase C y (PLCy)-Cam Kinase
(CaMK) pathway. Interestingly, studies have shown that both
proBDNF and mature BDNF have varying functions by differ-
ent intracellular pathways. The binding of proBDNF to p75NTR
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has been shown to promote long-term depression in rodent
hippocampal neurons, in contrast with long-term potentiation
by mature BDNF binding to TrkB.[15]
BDNF is translated and released in an activity-dependent
manner. The Bdnf gene consists of 11 exons in humans and a
single exon coding for the proBDNF protein. Bdnf transcription
is controlled by nine different promoters that are active in a
developmental, tissue specific, and activity-dependent man-
ner.[16] Transcription of Bdnf is initiated at each of the 5′
noncoding exons that are spliced into the common proBDNF
protein-coding 3′ exons. Alternatively, there are variable ATG
sequences upstream of the exons I, VII, and VIII in humans,
resulting in production of proBDNF with variable amino acid
lengths at the N-terminal end of the protein.[16] Bdnf has two
alternative polyadenylation sites, resulting in two distinct spe-
cies of mRNA with either a long or short 3′UTR. While BDNF
mRNA and protein are highly expressed in the hippocampus,
cerebral cortex, amygdala, and cerebellum in the mammalian
brain,[17] these BDNF transcripts are distributed in a structu-
rally distinct manner as well, with short 3′ UTR transcripts
present in the somata of hippocampal neurons, while the
long 3′ UTR transcripts are found in the dendrites.[18]
Studies in mice with a truncated long 3′ UTR demonstrated
deficits in synaptic pruning, enlargement of dendritic spines,
and selective impairment of long-term potential of dendrites
but not the soma of hippocampal neurons.[19] BDNF is
expressed to a lower extent in non-neural tissues such as
heart, kidney, lung, and testis.
The multiple promoters present in Bdnf results in context-
dependent responses to intracellular processes and extracel-
lular disturbances. Promoter IV is of particular interest in
that its expression is dependent on multiple transcriptional
regulators: both Ca2+ response elements and Ca2+ sensitive
transcription factors such as cyclic AMP-responsive element
binding protein (CREB),[20] and methylated CpG binding
protein.[21] Membrane depolarization and activation of glu-
tamate receptors such as N-methyl-D-asparate (NMDA)
receptors enhance BDNF expression.[22] Ca2+ dependent
neural activity induced by NMDA receptors stimulates tran-
scriptional expression of BDNF due to multiple Ca2
+-response elements in exons I and IV of Bdnf.[23]
Interestingly, CREB is tightly controlled by multiple signaling
pathways triggered by Ca2+ such as the rapidly accelerated
fibrosarcoma/MAPK/ERK and the CaMK; important pathways
for sensory stimuli and learning. Together, this suggests that
BDNF expression is strongly regulated by CREB; however,
CREB activation can be due to a myriad of Ca2+ induced
pathways.
The proBDNF precursor is a 32-kDa protein generated in
the endoplasmic reticulum and then cleaved to create 13-
kDa mature BDNF protein via furin protease in the trans-
Golgi network (TGN).[24] The pro-region of BDNF binds to
the lipid-raft associated sorting receptor carboxypeptidase E
(CPE) in the TGN and subsequently BDNF is shuttled into
secretory vesicles, relaying the importance of the pro-region
as a sorting motif.[25] A mutation (val66met) in the pro-
region results in poorer sorting of BDNF into vesicles [26]
and results in hippocampal volume loss [27], and altered
experience dependent plasticity in motor neurons in human
Alzheimer’s disease (AD) patients.[28] BDNF-containing vesi-
cles are transported to secretory sites by motor protein
Figure 1. BDNF function acts through various canonical signaling pathways
once bound to its preferred receptor TrkB to influence survival, neuronal out-
growth, synaptic plasticity, learning, neurogenesis and neuroprotection. Loss of
BDNF has been indicated in a number of neurodegenerative diseases, while
restoration or addition of exogenous BDNF has shown a physiologic therapeutic
effect.
Article highlights
● Brain-derived neurotrophic factor is a critical neurotrophin regulating
cell survival, neuronal outgrowth, and plasticity.
● Brain-derived neurotrophic factor regulates neurogenesis, synaptic
plasticity, and apoptosis via PI3K-AKT, MAPK, ERK, and y-CaM kinase
pathway.
● Dysregulation of brain-derived neurotrophic factor has been impli-
cated in many disorders including Alzheimer’s, Parkinson’s, and
Huntington’s disease.
● Delivery of brain-derived neurotrophic factor has been the major
hurdle to its use in a clinical setting.
● Engineered mesenchymal stem cells may circumvent many of the
issues surrounding brain-derived neurotrophic factor delivery.
This box summarizes key points contained in the article.
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complexes and can be released from the cell soma axon and
dendrites in a depolarization-dependent manner in vitro [29]
in response to Ca2+ influx as mentioned earlier. Interestingly,
mutant Huntingtin, the causative gene in Huntington’s dis-
ease (HD), appears to attenuate vesicular transport of BDNF
along microtubules in neurons [30] and wild-type Huntingtin
acts as a transcription factor to enhance cortical BDNF.[31]
Repression element silencing factor-1 (REST), a master regu-
lator of neuronal expression, has been shown to have a
strong association with Huntingtin and its normal function
disrupted in presence of mutant Huntingtin. REST is normally
found within the cytoplasm; however, mutant Huntingtin
causes translocation of REST into the nucleus and represses
several targets including BDNF.[32,33] This phenomenon is
reversed upon silencing of REST.[34]
The proposed mechanism of BDNF action as a neuronal
growth factor and synaptic regulator has been explored in
several studies. Axonal outgrowth in hippocampal neurons
is mediated by stabilization of cAMP/PKA activity following
BDNF-induced local elevation of TrkB, driving axon initia-
tion in undifferentiated neurites.[35] Both in vitro and in
vivo studies have shown that BDNF promotes axon elonga-
tion and branching of sensory neurons [36] as well as
increased dendritic outgrowth in BDNF-overexpressing
neurons in rat cortical slice cultures.[37] Increased expres-
sion of BDNF in transgenic mice demonstrated preganglio-
nic and axonal hypertrophy as well as increased synaptic
innervation of sympathetic neurons.[11] Adult mutant mice
with absent TrkB signaling during development showed
less presynaptic terminals, reduced excitatory number,
and altered structural morphology of synapses in the hip-
pocampus.[38] Furthermore, aberrant branching and prun-
ing of thalamic axon terminals was observed in conditional
TrkB knockout mice in the thalamus.[39]
Decreased synaptic proteins and vesicle release have been
shown in animal models with reduced TrkB signaling [40]
whereas BDNF exposure results in increased number of
docked synaptic vesicles in cultured hippocampal neurons.
[41] BDNF potentiates neuronal circuitry by modulating synap-
tic efficiency. Exogenous BDNF increases glutamate transmis-
sion in rodent brain slices of the hippocampus [42] and visual
cortex [43] and favors increased insertion of both NMDA and
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tors in the post-synapse of excitatory neurons,[44] important
functions for learning. BDNF is a strong modulator for axonal
development and synaptic connectivity in the mammalian
brain.
The neurogenic potential of BDNF has been well known
due to the intricate relationship between its preferential
receptor, TrkB, to cell survival and proliferation pathways.
However, BDNF has been implicated in a number of disease
phenotypes such as ischemic stroke and epileptic seizure.[45]
BDNF and TrkB expression in brain structures that are vulner-
able to temporal lobe epilepsy (amygdala, etc.) are elevated
following epileptic insult and acute infusion of BDNF into the
murine brain appears to induce seizure.[46,47] However,
opposing studies have shown that chronic infusion of BDNF
reduces potential of reaching an epileptic state [48] and BDNF
conditional knockout mice did not appear to demonstrate
significant altered epileptic state.[49] Together, this suggests
that while BDNF may have a role in epilepsy, it is not entirely
well understood.
1.2. BDNF therapies
Deficits in BDNF have been an observed phenomenon in a
number of diseases. Post-mortem studies in AD patients have
shown significantly decreased BDNF expression in the hippo-
campus, temporal, and frontal cortex.[50] Spinocerebellar
ataxia type 6 showed reduced BDNF mRNA expression in
human cerebellum and sequestration of BDNF to abnormal
loci in the neuron.[52] Reduced BDNF mRNA is observed in
dopaminergic neurons in Parkinson’s disease (PD) in compar-
ison to normal counterparts and reduced neuronal density
was correlated to total BDNF mRNA expression,[51] suggesting
that loss of BDNF compromised the well-being of neighboring
neurons.
BDNF impairment has been related to a number of neuro-
cognitive disorders (reviewed in [56]), particularly in anxiety
[57,58] and may contribute to the cognitive and emotional
disturbances observed in HD. It is interesting to note that
Huntingtin appears to be a regulator of BDNF transport and
presence of the mutant protein results in aberrant transport
and expression in hippocampal and cortical neurons, respec-
tively.[30] Association of REST with mutant Huntingtin results
in reduction of BDNF expression.[32,33] The BDNF protein is
necessary for medium spiny neurons (MSNs) survival;[54] how-
ever, striatal neurons only produce very low levels of neuro-
trophic factors and are dependent on BDNF to be produced in
the cerebral cortex and transported via corticostriatal tracts to
MSNs.[59] While it has been reported in experimental models
of neurodegenerative diseases that deep-brain stimulation,
specifically in the subthalamic nucleus, can increase BDNF
protein and mRNA levels in the striatum, functional recovery
was only observed in the presence of the stimulation,[60]
thereby limiting the long-term benefits without chronic expo-
sure to deep-brain stimulation.
Interestingly, it was found that patients with symptomatic
HD and lower levels of BDNF serum concentrations had sig-
nificantly worse motor and cognitive performances than indi-
viduals with normal BDNF levels.[54,55] It is known that BDNF
is very important for survival and differentiation of striatal
neurons and lower BDNF may be a reason why these neurons
deteriorate in HD.[55] Objective biochemical measures can
allow one to monitor the progression of HD, and peripheral
BDNF levels may become a potential marker to measure the
state of the disease and/or the effectiveness of a given treat-
ment.[55]
There have been considerable efforts in developing BDNF
as a therapeutic, given the large amount of evidence for its
role as a neuroprotective and neurogenic element and asso-
ciated deficiencies in a number of diseases. Treatment with
exogenous BDNF demonstrated sparing of forebrain choliner-
gic neurons [61] and reduction in Aβ peptide [10] in rat brains.
Early BDNF treatment in transgenic AD mice ameliorated cell
loss and increased synaptophysin in the entorhinal cortex,
while also demonstrating enhanced hippocampal fear condi-
tioning.[62] This same effect was observed in nonhuman
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primates.[63] Enhanced striatal innervation and reduced cell
loss were observed in a Parkinsonian nonhuman primate
model following BDNF infusion.[64] Arrest of hippocampal
neurogenesis results in impaired contextual fear conditioning
following directed irradiation of the hippocampus,[65,66] sug-
gestive that BDNF treatment results in enhanced neurogenesis
and synaptic connection.
Marked sparing of motor neuron damage from acute spinal
lesions is observed after administration of BDNF.[67–69]
Environmental enrichment through increased exercise rescued
low BDNF levels in R6 HD mice, reducing weight loss and
spared motor symptoms.[70] Interestingly, BDNF has been
implicated in some forms for neuropathic pain. Diabetic mice
showed synaptic dysfunction and both reduced BDNF mRNA
and protein.[71] Gamma-Aminobutyric acid (GABA) is down
regulated in the dorsal horn of spinal lesioned mice. This effect
is ameliorated by BDNF-induced GABA release following
intrathecal injections of NTF, resulting in reduced mechanical
hypersensitivity and thermal hyperalgesia in treated animals.
[72] Allodynia and hyperalgesia induced by chronic constric-
tion injury of the sciatic nerve in rats were reversed 1-week
following adeno-associated virus (AAV)-BDNF injections, sug-
gesting a potential therapy for chronic pain.[73] More recently,
cerebellar injections of a herpesviral vector encoding BDNF
prevented apoptosis of cerebellar granule cells and ataxic
phenotype in an induced Fredreich’s ataxia mouse model.[74]
Despite encouraging preclinical data using BDNF, the abil-
ity to deliver NTFs into the brain remains a challenge. NTFs are
large, polarized proteins that do not readily cross the blood–
brain barrier (BBB), necessitating delivery of NTFs directly into
the CNS. BDNF administration in animal models of amyloid
lateral sclerosis (ALS) demonstrated robust cell survival in
spinal motor neurons and corticospinal neurons.[75] Ensuing
clinical trials demonstrated BDNF presence in the cerebral
spinal fluid following intrathecal administration of recombi-
nant BDNF. While generally well-tolerated, high dose BDNF
groups experienced adverse elements such as sleep distur-
bance and abnormal behavioral effects that necessitated
dose reduction.[76] The large-scale, Phase III BDNF Study
Group Trial enrolled 1135 patients and did not demonstrate
statistical significance in a survival effect following subcuta-
neous recombinant BDNF administration.[77] Later, clinical
trials were performed in smaller numbers and demonstrated
the same lack of statistical significance following intrathecal
BDNF infusion. Retrospective analysis suggests NTF adminis-
tration either subcutaneously or intrathecally are unable to
reach degenerating neurons [78,79] or cross the BBB [80–82]
effectively. It is important to note that the associated adverse
events observed during the BDNF Study Group were due to
dose and not an innate toxicity from BDNF. A similar phenom-
enon was seen in mice with AAV-BDNF overexpression at high
levels.[83]
2. Delivery of BDNF in the CNS
With the knowledge that BDNF is neuroprotective, researchers
have attempted to increase BDNF production from endogen-
ous cells within the striatum via adenoviral injections [84,85]
or through AAV vector injections into the striatum [86] prior to
quinolinic acid lesions. Both groups observed an increase in
the numbers of cells expressing Dopamine- and cAMP-regu-
lated phosphoprotein of 32 kDa (Darpp32; specific to MSNs)
relative to lesioned control animals. Interestingly, in the latter
group, an AAV was also utilized to increase glial-derived neu-
rotrophic factor release.
New approaches in identifying an optimal delivery method
for BDNF have been explored in recent years. Transplantation
of neural stem cells in an alpha-synuclein mouse improved
performance in cognitive and motor domains following
restoration of BDNF expression,[87] mimicking effects seen in
AAV-mediated BDNF.[88] Nanoparticle-mediated therapy ele-
vated BDNF in the hippocampus mitigated levels of Aβ and
tau proteins while augmenting neuronal cell survival in AD
transgenic rats.[89] Overexpression of BDNF using mesenchy-
mal stem cells (MSCs) in HD mouse models have shown
amelioration of behavioral deficits in HD mouse models,[90]
increased striatal volume and neurogenesis.[12]
Effective delivery of BDNF for neurological disorders
remains a major challenge due to its very short half-life,
which severely limits the effectiveness of the recombinant
protein. Several studies have examined various exogenous
delivery methods that may be utilized to translate BDNF-
based therapeutics to the clinic. Benraiss et al. used AAV
vectors to express BDNF in striatal neurons and demon-
strated that AAV delivery of BDNF-induced neurogenesis
and promoted a longer lifespan in a murine model of HD.
[91] Interestingly, this benefit was potentiated by a factor
secreted by mesenchymal stem/stromal cells, noggin.[92–
94] Despite this success, the use of AAV in the clinic has
proven difficult due to host immunogenicity to the virus
and limited biodistribution.[95] In comparison, MSCs
demonstrate paracrine effects such as local immune mod-
ulation and release of beneficial factors such as human
growth factor, fibroblast growth factor-2, insulin growth
factor 1 and vascular endothelial growth factor (VEGF),
BDNF, Dickkopf-related protein 1, b-NGF that favor growth.
[96] Furthermore, MSCs home to sites of inflammation,
apoptosis, and hypoxia, [97] making it an attractive target-
ing vehicle for sites of injury.
Our group at the Institute for Regenerative Cures at the
University of California, Davis have tested the safety and effi-
cacy of genetically engineered human bone marrow MSCs in
transgenic HD mouse models and published the results of our
investigative new drug-enabling studies in Molecular Therapy.
[12] These cells were prepared in a clinically compliant man-
ner, mimicking cells proposed for a Phase I clinical trial. The
YAC128 and R6/2 transgenic HD mouse models were used for
behavioral and histological studies following transplantation
to measure efficacy of MSC/BDNF as a putative therapy for HD.
Human MSC genetically engineered to produce BDNF
reduced the total striatal atrophy observed in HD mice by
approximately 50%, as compared to untreated transgenic
mice. It was observed that engineered MSC also induced
significant neurogenesis, a potential mechanism of recovery
following BDNF administration. Engineered MSC also provided
significant behavioral recovery in transgenic mouse model of
HD. Following transplantation, treated mice displayed signifi-
cantly less anxiety-like behaviors than untreated transgenic
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mice. These results, along with the abundance of peer-
reviewed articles (see [98]) provide compelling evidence for
the proposed use of genetically engineered MSC as a candi-
date therapy for changing the trajectory of disease progres-
sion in patients diagnosed with early-stage HD.
MSCs were chosen as the delivery platform for BDNF since
they are known to secrete a variety of neurotrophic and other
factors that reduce inflammation, reduce programmed cell
death, enhance connections between neurons, and reduce
cell toxicity.[98] MSCs have been shown to be readily engi-
neered using viral vectors to robustly deliver growth factors.
[99,100] Using gene-modified MSCs as a delivery strategy
addresses certain safety concerns involved with the direct
use of viral vectors, as MSCs do not permanently engraft into
host tissues. In addition, MSCs do not require immunosuppres-
sion following allogeneic transplantation, and have a strong,
demonstrable safety profile in clinical trials.[96,101] Most
importantly, MSCs have been shown to be well-tolerated in
phase I/II clinical trials without adverse events in a variety of
diseases with no tissue matching. Currently, Atherys, SanBio,
and Brain-Storm Therapeutics have all concluded Phase II
clinical trials with MSCs with no reported adverse effects in
either acute or chronic neurodegenerative insults such as
ischemic stroke or amyotrophic lateral sclerosis. Importantly,
Brain-Storm Cell Therapeutics concluded a phase I/IIa clinical
trial in patients with amyotrophic lateral sclerosis using auto-
logous MSCs induced to express neurotrophic factor (NurOwn)
with mild and transient adverse effects reported. Strikingly,
treated ALS patients demonstrated slowed disease progres-
sion following the conclusion of the phase IIa trial with
improvements in breathing and reduced motor decline com-
pared to pretreatment.[102]
MSC/BDNF combine the beneficial effects of BDNF admin-
istration to the striata along with the benefits of MSC secreted
factor supplementation (e.g. noggin). Unlike direct BDNF deliv-
ery via viral vector injection or recombinant protein adminis-
tration into the brain, MSCs migrate into areas of tissue
damage and have been shown to have numerous tissue heal-
ing effects (reviewed in [98]). Studies have shown that MSCs
do not permanently engraft into host tissues; however, the
duration and strategic localization of BDNF production should
be adequate to produce a beneficial effect that will outlast the
survival of MSCs.[12,103]
2.1. Alternative disease indications for MSC-delivered
BDNF
The adult nervous system has limited repair capabilities after
injury due to intrinsic neuronal properties which prevent effec-
tive reinnervation. However, remaining uninjured axons can
develop a few collaterals that reinnervate denervated neurons
and this response is increased by NTFs such as BDNF. In
addition, severed neurons may be rescued from degenerative
atrophy and apoptosis upon treatment with BDNF.
Moreover, increased interest in BDNF as a co-therapeutic
for acute spinal injury has been expressed due to its role in
synaptic modulation and axonal regeneration. Enhanced BDNF
is observed in subpopulations of motor nuclei in spinalized
rats that underwent exercise, suggesting BDNF as marker for
increased motor innervation.[104] Reduced BDNF is observed
in both spared and resected dorsal root ganglia following
partial ganglionectomy, but BDNF increased significantly sev-
eral days following operation in spared ganglia, suggesting a
role for BDNF in neuroplasticity following acute injury.[105]
Increased BDNF application in spinal lesions in mice demon-
strated increased sprouting of injured neurons.[106]
While multiple studies have demonstrated that BDNF can
promote axonal regeneration and rewiring of injured nerve
fibers, outcomes vary in their therapeutic effect. BDNF treat-
ment may benefit from complementary signaling proteins
such as those produced by MSC. After spinal cord injury,
pro-apoptotic factors are typically upregulated; however,
BDNF may induce pro-survival signaling cascades and rescue
neurons that take part in restructuring neuronal circuitry.
Reinnervation of muscles is also critical to re-establishing
the functional activity of the muscle–skeletal apparatus after
peripheral nerve injuries. Several studies have determined that
BDNF is critical to the repair of damaged peripheral nerves,
and is upregulated via epigenetic mechanisms for several days
post-injury.[107–109] Studies have demonstrated that BDNF
induced axonal regeneration and axonal sprouting from the
proximal end of cut nerves into denervated nerve stumps.
[110,111] Taken together, numerous studies have demon-
strated that BDNF-related therapies may prove beneficial for
spinal cord and peripheral nerve injuries (Figure 2).
3. Expert opinion
BDNF is a crucial NTF for development and mature neuronal
health. It is highly implicated in numerous neurological dis-
eases such as AD, PD, HD and other neurodegenerative dis-
orders, making it a prime therapeutic agent. Countless studies
have shown the therapeutic potential of BDNF in promoting
axonal regrowth, preserving synaptic strength, sparing neuro-
nal loss in a number of neurodegenerative disease models,
and facilitating reinnervation of neurons in acute CNS injury.
Despite numerous preclinical studies providing evidence on
the therapeutic potential of BDNF, there has been difficulty in
translating this work to the clinic. The methods to deliver
BDNF to the CNS in a safe and physiologically relevant manner
have historically been lacking. The use of recombinant protein
is fraught with issues of protein degradation, immune
response, and an inability to cross the BBB in appreciable
quantities. The use of viral vectors also runs the risk of
immune response as well as insertional mutagenesis and the
potential of overloading the endogenous neurons with excess
BDNF, a concern in cases of epilepsy. As such, researchers
must adapt existing technologies and develop new methods
to surmount the current challenges in delivering NTFs
clinically.
The use of MSC as a delivery platform for NTF, specifi-
cally BDNF, holds great promise to advance the clinical use
of NTF replacement or supplementation. The ease with
which MSC can be engineered opens the door to the pos-
sibility of using this cell-based delivery system to advance
poly-therapeutics such as trophic support in addition to
potent gene editing molecules. Our research team at the
Institute for Regenerative Cures at the University of
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California, Davis has specifically focused on translating pro-
mising preclinical data using MSC as a delivery platform for
trophic factors including BDNF and VEGF for HD and critical
limb ischemia, respectively. We have validated the preclini-
cal efficacy and safety of MSC engineered to produce BDNF
in transgenic mouse models of HD. The results from our
animal studies indicate that transplantation of genetically
engineered MSC are safe and provide significant behavioral
and neuropathological benefits in two transgenic mouse
models of HD.
We are currently conducting duration, biodistribution, and
large animal (porcine) studies as recommended by the FDA for
Investigational New Drug approval to potentially start a Phase I
safety and tolerability study transplanting genetically engi-
neered MSC in early-stage HD patients (HD-CELL). In anticipa-
tion of HD-CELL our group is conducting a Phase I
observational trial (PRE-CELL NCT01937923) to longitudinally
assess disease progression prior to potentially enrolling patients
in a therapeutic trial. The parallel design of the preclinical and
clinical observations not only pre-identifies a patient population
that would be eligible to receive our MSC/BDNF stem cell
product, but allows each subject to essentially serve as their
own control when addressing disease progression. We feel that
our strong preclinical data, along with the robust evidence in
the literature that MSC-based delivery of BDNF or other NTF
holds great promise to treat not only HD, but other neurologi-
cal diseases or damage to the CNS.
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